Apotex Health Corp., Canada’s largest pharmaceutical manufacturer, is expanding its initial public offering (IPO) to $1.3 billion. This decision comes in response to significant investor demand for its shares, which are priced at $24 each on the Toronto Stock Exchange.
IPO Details and Investor Confidence
The company initially targeted $1 billion for its IPO and aimed to price shares between $20 and $24. However, due to strong interest, it increased the offering by 30%. This upsizing is viewed positively within Canada’s capital markets, where IPOs have faced challenges in recent years.
- IPO Size: Increased to $1.3 billion
- Share Price: $24 each
- Initial Target: $1 billion
- Increased Offering Percentage: 30%
Alongside the IPO, Apotex’s private equity backer plans to sell $450 million worth of shares, a significant increase from the initially planned $150 million. The remaining $850 million will aid Apotex in reducing its debt.
Market Context and Historical Significance
This IPO marks the largest in Canada since the $1.4 billion offering by Definity Financial Corp. in 2021. However, it is launched amidst fluctuations in American stock markets, particularly a downturn in the Nasdaq Composite Index, which could impact the performance of Apotex’s newly listed shares.
Company Background and Operations
Founded in 1974 by Barry Sherman, Apotex is known for producing generic medications. It operates on a global scale, with over 6,500 employees producing 25 billion doses annually for markets in 70 countries. In its last fiscal year, sales distribution was as follows:
| Region | Percentage of Sales |
|---|---|
| Canada | 45% |
| United States | 46% |
| International | 9% |
After the tragic death of Barry Sherman in December 2017, Apotex was sold to SK Capital Partners, a private equity firm. SK Capital is participating in the IPO, while remaining a significant stakeholder in the company.
Expansion and Strategic Initiatives
In recent years, Apotex has diversified its product offerings beyond generics. The company now includes a range of treatments such as liquids, inhalers, and biosimilars. Notable acquisitions include:
- Searchlight Pharma Inc.: Acquired for $502 million in 2024, focusing on patented drugs.
- CanPrev Natural Health Products: Purchased for $184.5 million, expanding into vitamins.
While these strategic moves aim at growth, they have contributed to an increase in Apotex’s debt, which reached $2.9 billion as of March 31. This figure has more than doubled over two years.
Overall, Apotex’s IPO reflects a strong demand for its robust pharmaceutical portfolio and a hopeful outlook in the market amid potential challenges.
